Alimta

... Breaking News: Hana Biosciences Announces Positive Interim Results From a Phase I Trial of Talotrexin (PT-523) in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) BODY { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BACKGROUND: #ececec; PADDING-BOTTOM: 0px; MARGIN: 0px; FONT: 85% Arial, Helvetica, sans-serif; PADDING-TOP: 0px } Log in Register Now UPDATED 11/14/2005 8:55:00 AM EST Contact Us Mary Ann Liebert, Inc.

About GEN Home In The News Breaking News Sticky Ends Online Current Issue New Products On The Web Past Issues Calendar of Events Classifieds View Listings Submit a Listing Web Resources Subscribe to GEN Reprints Advertise in GEN Media Kit Mailing List Rental Partnership Opportunities Editorial Editorial Calendar Meet the GEN Editors Gen database of Biotech Firms Home » In The News » Breaking News Breaking News Email article to a colleague Printer friendly version Hana Biosciences Announces Positive Interim Results From a Phase I Trial of Talotrexin (PT-523) in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) 11/14/2005 7:58:00 AM EST Hana Biosciences (AMEX:HBX), a South San Francisco-based biopharmaceutical company focused on advancing cancer care, announced today positive interim data from an ongoing, multi-center Phase I clinical study evaluating single agent Talotrexin (PT-523) in relapsed or refractory advanced non-small cell lung cancer...

Read more...